Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLAXO (GLX) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (203)	1/6/1999 10:10:00 AM
From: Zoltan!	Respond to of 222

Dow Jones Newswires -- January 6, 1999 Chiroscience Shrs Up 4.7% On Press Tip, Zeneca Rumor>U.CCC By Michael Reid LONDON (Dow Jones)--Shares of Chiroscience PLC (U.CCC) rallied 4.7% Wednesday on positive press comment and on speculation that a rival bid for Zeneca PLC (ZEN), which owns the marketing rights for Chiroscience's Chirocaine anesthetic, could yet preserve its links with the pharmaceutical major. At 1212 GMT, Chiroscience shares were up 12 pence at 267.5 pence, having traded as high as 275 pence earlier in the session. Volume was about 305,000 shares. Retail buying in small tranches was the key driver of the gain, with analysts citing an upbeat report in Wednesday's Daily Telegraph. But also contributing is the persistent rumor that Zeneca's planned merger with Sweden's Astra AB (A) may be threatened by a rival bid. Among market participants Glaxo Wellcome PLC's (GLX) name has been mentioned, although most analysts think that tie-up is unlikely. Zeneca told Dow Jones Newswires it won't comment on market rumors. But if such a bid did emerge, it may solve Chiroscience's dilemma with Chirocaine, its long-acting local anesthetic licensed to Zeneca for marketing everywhere except Japan. Zeneca, which has expertise in anesthetics, took on Chirocaine to compete with rival Astra's anesthetics stable of Marcaine and Naropin. That was before it decided to hook up with Astra. Fears that Zeneca might therefore either not want, or not be permitted by regulators, to keep Chirocaine's marketing rights fueled a December markdown in Chiroscience's share price. But now the rumor-mill has come a full circle. Drug stocks gained strongly Monday and Tuesday, sparking the rival-bidder rumor. Zeneca was among the risers; shares have added almost 6% since Monday's open. At 1212 GMT, Zeneca shares were changing hands at 2828 pence, up 54 pence on the day. However, some observers reckon Zeneca's gains have been fueled by technical factors such as re-weightings by institutional buyers. Glaxo Wellcome, which gained 8% Monday and Tuesday, was up a further 37 pence, or 1.7%, at 2256 pence, by 1212 GMT. SmithKline Beecham PLC (SBH), which gained 5.6% to Tuesday's close, was up 17 pence at 904 pence. interactive.wsj.com

To: Henry Niman who wrote (203)	1/6/1999 10:11:00 AM
From: Zoltan!	Read Replies (1) \| Respond to of 222

Dow Jones Newswires -- January 6, 1999 BT Alex. Brown Favors Defensive Stocks For Europe In 1999 LONDON (Dow Jones)--BT Alex. Brown is taking a cautious approach to Europe in 1999, favoring defensive stocks in its Pan-European 15 portfolio. BTAB said the portfolio "largely favors defensive plays - financially and economically defensive companies - and those expected to benefit from restructuring." The fifteen stocks are: BG PLC (BRG), British Telecommunications PLC (BTY), Glaxo Wellcome PLC (GLX), Canal Plus SA (F.CLP), Endesa SA (ELE), Mannesmann AG (G.MMN), Nokia Corp. (NOKA), Novartis AG (Z.NOV), Pearson PLC (U.PSO), Powergen PLC (PWG), Rhone-Poulenc SA (RP), Richemont Securities AG (O.RCH), UBS AG (Z.UBS), Telecom Italia SpA (TI) and VNU NV (N.VNU). Nokia, UBS and Novartis were part of BTAB's Pan-European 15 portfolio last year. interactive.wsj.com